Últimos ensayos


EudraCT Number: 2006-000110-21 Sponsor Protocol Number: BT959 Start Date: 2006-11-21
Sponsor Name: Biotest AG
Full Title: An open, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application for perinatal prophylaxis in infan...
Medical condition: Healthy mature male and female neonates of gestational week ≥ 37+0 with indication for hepatitis B prophylaxis due to a HBsAg positive mother.
Disease: Version SOC Term Classification Code Term Level
8.1 10054130 Hepatitis B immunisation LLT
Population Age: Newborns, Under 18 Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: (No results available)

EudraCT Number: 2006-003109-23 Sponsor Protocol Number: 0518-021 Start Date: 2006-11-21
Sponsor Name: Merck & Co., Inc.
Full Title: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK- 0518 Versus Efavirenz in Treatment Naïve HIV-Infected Patients, Each in Co...
Medical condition: HIV Infection
Disease: Version SOC Term Classification Code Term Level
8.1 10020162 HIV infection CDC Group I LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed) FR (Completed) IT (Completed) ES (Completed)
Trial results: View results
EudraCT Number: 2006-002852-13 Sponsor Protocol Number: BPI-CT-005 Start Date: 2006-11-21
Sponsor Name: Bexel Pharmaceuticals Inc.
Full Title: Double blind, placebo-controlled dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes to assess efficacy on glucose-profile, triglycerides and blood pressure ...
Medical condition: dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: (No results available)

EudraCT Number: 2005-003644-59 Sponsor Protocol Number: CASM981CDE17 Start Date: 2006-11-21
Sponsor Name: University of Heidelberg
Full Title: A two months study of the utility of Elidel cream 1% (pimecrolimus) in the long term management of atopic hand eczema.
Medical condition: chronically relapsing atopic hand eczema
Disease: Version SOC Term Classification Code Term Level
8.1 10003641 Atopic eczema LLT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2006-000487-92 Sponsor Protocol Number: SPJK/06/01 Start Date: 2006-11-21
Sponsor Name: Royal College of Surgeon's Ireland
Full Title: A Phase II, Randomised, Double Blind, Placebo Controlled Study examining the suitability of Phenytoin Sodium Topical Gel in the treatement of Venous Ulcers
Medical condition: Venous ulcers in the lower leg.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IE (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2006-001956-11 Sponsor Protocol Number: 08062 Start Date: 2006-11-21
Sponsor Name: Celgene International SARL
Full Title: Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC
Medical condition: Small Cell Lung Cancer (extensive stage)
Disease: Version SOC Term Classification Code Term Level
8.1 10041068 Small cell lung cancer extensive stage LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BE (Completed) GB (Completed) IT (Completed) NL (Completed)
Trial results: View results
EudraCT Number: 2006-003658-47 Sponsor Protocol Number: F02207 GE 3 03 Start Date: 2006-11-21
Sponsor Name: Pierre Fabre Médicament - IRPF
Full Title: Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
Medical condition: Major Depressive Disorder
Disease: Version SOC Term Classification Code Term Level
8.1 10012378 Depression LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Completed)
Trial results: View results

EudraCT Number: 2004-003833-15 Sponsor Protocol Number: MEU04/118A Start Date: 2006-11-21
Sponsor Name: South Manchester University NHS Trust [...] 1. South Manchester University NHS Trust 2. Medicines Evaluation Unit 3. University of Manchester
Full Title: A randomised parallel group study to investigate the effect of Seretide withdrawal in COPD using non-invasive biomarkers and physiological measurements
Medical condition: Chronic Obstructive Pulmonary Disease
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: View results
EudraCT Number: 2006-002384-12 Sponsor Protocol Number: D4200C00044 Start Date: 2006-11-21
Sponsor Name: AstraZeneca AB
Full Title: A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474(ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Car...
Medical condition: Non-small cell lung cancer
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed)
Trial results: View results

EudraCT Number: 2006-000476-33 Sponsor Protocol Number: GC-SU-2006 Start Date: 2006-11-20
Sponsor Name: Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik
Full Title: An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer
Medical condition: Chemorefractory metastatic adenocarcinoma of stomach, esophagogastric junction and lower esophagus (Barrett carcinoma)
Disease: Version SOC Term Classification Code Term Level
8.1 10017758 Gastric cancer LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results
3
Suscribir